Table 1 Clinical characteristics.
From: DNA methylation markers in the diagnosis and prognosis of common leukemias
Characteristic | AML | ALL | Normal |
|---|---|---|---|
Total (n) | 194 | 136 | 754 |
Gender | |||
Femal-no. (%) | 90 (46) | 42 (31) | 401 (53) |
Male-no. (%) | 104 (54) | 94 (69) | 353 (47) |
Age at diagnosis (year) | |||
Median | 55 | 5 | 63 |
Range | 18–88 | 1–13 | 19–101 |
White race-no/total no. (%) | |||
White | 176 (91) | 0 | 504 (67) |
Asian | 2 (1) | 136 (100) | 7 (1) |
Other | 16 (8) | 0 | 243 (32) |
White cell count at diagnosis (×109/L) | |||
Mean | 37.94 ± 30.72 | 8.15 ± 5.78 | NA |
Median | 17 | 5 | NA |
FAB subtype — no. (%) | |||
AML with minimal maturation: M0 | 19 (10) | NA | NA |
AML without maturation: M1 | 42 (22) | NA | NA |
AML with maturation: M2 | 43 (22) | NA | NA |
Acute promyelocytic leukemia: M3 | 19 (10) | NA | NA |
Acute myelomonocytic leukemia: M4 | 41 (21) | NA | NA |
Acute monoblastic or monocytic leukemia: M5 | 22 (11) | NA | NA |
Acute erythroid leukemia: M6 | 3 (1.5) | NA | NA |
Acute megakaryoblastic leukemia: M7 | 3 (1.5) | NA | NA |
ALL-L1 | NA | 74 (55) | NA |
ALL-L2 | NA | 37 (27) | NA |
ALL-L3 | NA | 14 (10) | NA |
Other subtype | 2 (1) | 11 (8) | NA |
Cytogenetic risk group-no (%) | |||
Favorable (Low risk) | 36 (19) | 19 (14) | NA |
Intermediate (Standard risk) | 110 (57) | 64 (47) | NA |
Unfavorable (High/Very high risk) | 43 (22) | 39 (29) | NA |
Missing data | 3 (2) | 14 (10) | NA |
